Literature DB >> 34134782

The expression of miRNA-152-3p and miRNA-185 in tumor tissues versus margin tissues of patients with chemo-treated breast cancer.

Asma Safi1,2, Soheila Delgir2, Khandan Ilkhani2, Azam Samei3, Seyyed Reza Mousavi2, Zahra Zeynali-Khasraghi2, Milad Bastami4, Mohammad Reza Alivand5.   

Abstract

OBJECTIVE: Breast cancer (BC) is the most significant and lethal type of cancer in women. Although there are many newly develop chemotherapy drugs for patients with BC treating at various stages, drug resistance is the most important obstacle in their effectiveness for BC treatment. On the other hand, microRNAs are considered key regulators of genes involved in carcinogenesis and chemoresistance in cancers. The purpose of this study was to evaluate the role of miR-152-3p and miR-185 in intrinsic chemoresistance and proliferation of BC. In addition, the potential role of these miRNAs during chemoresistance was evaluated through possible signaling pathways.
RESULTS: Here, miR-152-3p was significantly downregulated in tumor tissues compared to the corresponding margin tissues in patients with BC (p-value ≥ 0.04407 and fold change = - 2.0552). In contrast, no statistically significant difference was observed in the miR-185 expression between the two groups. Furthermore, no significant correlation was found between the expression of these two miRNAs and subfactors, including cancer family history, abortion, and age. Downregulation of miR-152-3p could be considered a promising regulator of BC chemoresistance.

Entities:  

Keywords:  Breast cancer; Chemoresistance; Drug resistance; PI3K/AKT pathway; miR-152; microRNAs

Year:  2021        PMID: 34134782     DOI: 10.1186/s13104-021-05647-z

Source DB:  PubMed          Journal:  BMC Res Notes        ISSN: 1756-0500


  34 in total

Review 1.  Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure.

Authors:  Theodor H Lippert; Hans-Jörg Ruoff; Manfred Volm
Journal:  Arzneimittelforschung       Date:  2008

Review 2.  Epidemiology of breast cancer.

Authors:  T J Key; P K Verkasalo; E Banks
Journal:  Lancet Oncol       Date:  2001-03       Impact factor: 41.316

Review 3.  Biomarkers and multiple drug resistance in breast cancer.

Authors:  L O'Driscoll; M Clynes
Journal:  Curr Cancer Drug Targets       Date:  2006-08       Impact factor: 3.428

4.  lncRNA NEAT1 is closely related with progression of breast cancer via promoting proliferation and EMT.

Authors:  M Zhang; W-B Wu; Z-W Wang; X-H Wang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-03       Impact factor: 3.507

Review 5.  Molecular mechanisms of drug resistance.

Authors:  D B Longley; P G Johnston
Journal:  J Pathol       Date:  2005-01       Impact factor: 7.996

Review 6.  The Engaged Role of Tumor Microenvironment in Cancer Metabolism: Focusing on Cancer-Associated Fibroblast and Exosome Mediators.

Authors:  Khandan Ilkhani; Milad Bastami; Soheila Delgir; Asma Safi; Shahrzad Talebian; Mohammad-Reza Alivand
Journal:  Anticancer Agents Med Chem       Date:  2021       Impact factor: 2.505

7.  HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

Authors:  Christiane Knuefermann; Yang Lu; Bolin Liu; Weidong Jin; Ke Liang; Ling Wu; Mathias Schmidt; Gordon B Mills; John Mendelsohn; Zhen Fan
Journal:  Oncogene       Date:  2003-05-22       Impact factor: 9.867

8.  MicroRNA-mediated drug resistance in breast cancer.

Authors:  Kristy R Kutanzi; Olga V Yurchenko; Frederick A Beland; Vasyl' F Checkhun; Igor P Pogribny
Journal:  Clin Epigenetics       Date:  2011-06-27       Impact factor: 6.551

9.  Mesenchymal stem cells confer chemoresistance in breast cancer via a CD9 dependent mechanism.

Authors:  Mujib Ullah; Asma Akbar; Nathan Norton Ng; Waldo Concepcion; Avnesh S Thakor
Journal:  Oncotarget       Date:  2019-05-28

10.  Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects.

Authors:  Ana-Maria Florea; Dietrich Büsselberg
Journal:  Cancers (Basel)       Date:  2011-03-15       Impact factor: 6.639

View more
  1 in total

1.  Evaluation of circulating small extracellular vesicle-derived miRNAs as diagnostic biomarkers for differentiating between different pathological types of early lung cancer.

Authors:  Yi-Fang Jiang; Shan-Na Wei; Nan Geng; Wen-Wen Qin; Xin He; Xiu-Huan Wang; Yao-Pu Qi; Shan Song; Ping Wang
Journal:  Sci Rep       Date:  2022-10-13       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.